



P-BIO Pledge 4 COVID:

Contribution of Portuguese Biotech Start-ups

The world has come together to fight COVID-19 and the EU initiated a pledge for fund research in 3 key areas. Portugal participated actively in the EUR 7.4bn fund raise. Our in cash contribution is complemented by an active cluster of innovative companies developing unique solutions.



Vaccine

GLOBAL PARTNERSHIPS FOR COVID-19



Diagnostics



Therapeutics

HOW PORTUGUESE START-UPS ARE RESPONDING

		VACCINE	DIAGNOSTICS	THERAPEUTICS	DEVICES
Biosurfit	Development of an integrated solution to screening COVID-19 patients		●		
CEiiA	Development of a ventilator for COVID-19 patients				●
CellmAbs	Study of aberrant molecular structures as possible neutralizer antibody for COVID-19			●	
Crioestaminal	Development of cellular therapy for COVID-19 patients treatment			●	
GenIbet	GMP production of COVID-19 vaccine for clinical trials	●			
HeartGenetics	Development of a genetic test to vitamin D polymorphisms to prevent and decrease the disease severity		●		
Immunethep	Development of vaccine for SARS-CoV-2	●			
LiMM	Development of drugs to mitigate COVID-19 infection			●	
Matera	Development of an anti-microbial solution to eliminate SARS-CoV-2				●
MyBiome	Development of therapy based in intestinal microbiota, to reduce individual susceptibility to SARS-CoV-2			●	
Nano4	Colorimetric molecular detection system for COVID-19		●		
Stab Vida	Small pocket test which detects the virus presence, easy to use and at a low cost (about EUR 20)		●		
SWORD Health	Rehabilitation program to improve breathing capacity in recovered patients from COVID-19				●
TonicApp	Aggregator of digital resources necessary for helping doctors on their work during the pandemic				●

MORE INFORMATION www.science4covid19.pt

SUPPORT



XXII GOVERNO

ORGANIZATION



P-BIO

Portugal's Biotechnology Industry Organization
Associação Portuguesa de BioIndústria